Therapy for neuroendocrine tumors may be improved by patient-specific dosimetry

Therapy for neuroendocrine tumors may be improved by patient-specific dosimetry
Location of spheric volume of interests in vertebrae. (A–C) Volumes of interest in SPECT/CT images of patient without skeletal metastases. (D–F) Spheric volumes of interest in SPECT/CT images of patient with skeletal metastasis in thoracic vertebra 7. Credit: Linn Hagmarker, PhD, Sahlgrenska Academy, University of Gothenburg, Sweden.

In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients, according to new research published in the October issue of The Journal of Nuclear Medicine. By tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment.

"The present study aimed to develop a method for patient-specific determination of activity in marrow, enabling a more personalized dosimetry," explains Linn Hagmarker, Ph.D., a student at the Department of Radiation Physics at the Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden. "Personalized bone marrow dosimetry can be used as a factor to prevent bone marrow toxicity during treatment and to identify the risk for developing myelodysplastic syndrome and acute leukemia."

The Swedish team developed a hybrid planar and SPECT imaging method to determine the bone marrow absorbed dose. In a of 46 patients treated with 177Lu-DOTATATE, it was established that this planar image-based method was not influenced by skeletal metastases, whereas hybrid dosimetry methods, based on planar and SPECT images, was influenced by skeletal metastases and by the vertebrae used for SPECT quantification. All methods demonstrated statistically significant dose-response correlations. The planar method had the best correlation for patients without skeletal metastasis, and the hybrid methods had the best correlation for patients overall, including the cohort with skeletal metastasis.

In neuroendocrine tumor treatment, different methods of predicting patient response may be required for different patients. Dr. Linn Hagmarker, from Sahlgrenska Academy, University of Gothenburg, Sweden, explains that by tailoring the method to the specific patient, physicians may better predict the effectiveness of treatment. The research is featured in The Journal of Nuclear Medicine Credit: Linn Hagmarker, PhD, Sahlgrenska Academy, University of Gothenburg, Sweden.

The study results show that different dosimetry methods might be required for optimal prediction of hematologic toxicity in patients with and without skeletal metastases.

"Since the active bone marrow varies within vertebrae, we determined the activity concentration in vertebrae using several methods," said Hagmarker. "We also investigated whether the bone marrow absorbed dose correlated with hematologic response early during treatment. The image-based dosimetry methods demonstrated that increased absorbed bone marrow doses result in higher platelet toxicity, and the platelet response is influenced by infiltrating metastases."

She adds, "The absorbed dose to the spleen also influences the platelet response by acting as a reservoir for platelets. In addition, age, gender, and pre-treatment (which all influence the vertebrae constitutents of adipose and active bone marrow cells) must be incorporated when modeling and developing predictive models for toxicity."

Looking at further implications of this research, Hagmarker notes, "Current evidence indicates that kidneys can tolerate mean absorbed doses above the general dose-limit. Recent studies have also reported the use of retreatment for patients with progressed disease. If higher renal mean absorbed doses are accepted, higher total activity could be administered, and might become the dose-limiting factor."


Explore further

Wearable technology to personalize Lu-177-DOTATATE therapy for NETs

More information: Linn Hagmarker et al, Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases, Journal of Nuclear Medicine (2019). DOI: 10.2967/jnumed.118.225235
Journal information: Journal of Nuclear Medicine

Provided by Society of Nuclear Medicine and Molecular Imaging
Citation: Therapy for neuroendocrine tumors may be improved by patient-specific dosimetry (2019, October 29) retrieved 12 December 2019 from https://medicalxpress.com/news/2019-10-therapy-neuroendocrine-tumors-patient-specific-dosimetry.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments